Search This Blog

Monday, March 24, 2025

Abivax 2024 results, update

   Cash balance of EUR 144.2M as of December 31, 2024; cash runway into Q4 2025

  • Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)